Prelude Therapeutics to Attend Upcoming Healthcare Conferences

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, has announced its participation in two prominent healthcare conferences in June. Listed on the Nasdaq as PRLD, the company is set to present at the Jefferies Global Healthcare Conference 2024 and the Goldman Sachs 45th Annual Global Healthcare Conference.

At the Jefferies Global Healthcare Conference, scheduled for June 6th at 1:30 p.m. ET, Prelude’s CEO, Kris Vaddi, Ph.D., will engage in a fireside chat. A live webcast of this discussion will be available for real-time viewing. The second event, the Goldman Sachs 45th Annual Global Healthcare Conference, will take place on June 12th at 10:40 a.m. ET. During this event, Dr. Vaddi will deliver a corporate presentation. The live webcasts of both events will be accessible to the public through specific links provided by the company and will be archived on Prelude’s website for 90 days.

Prelude Therapeutics focuses on developing novel drug candidates that target critical pathways in cancer cells. The company’s pipeline includes several innovative compounds tailored to treat cancers in patients with specific needs. Among these candidates are PRT3789, an intravenously administered, potent, and highly selective SMARCA2 degrader; PRT2527, a potent and highly selective CDK9 inhibitor; and PRT3645, a next-generation CDK4/6 inhibitor. Additionally, Prelude is working on PRT7732, an orally bioavailable, potent, and highly selective SMARCA2 degrader.

In addition to its internal projects, Prelude has established a collaboration with AbCellera to discover, develop, and commercialize up to five next-generation antibody-drug conjugate (ADC) products. This partnership aims to combine AbCellera’s expertise in antibody discovery and development with Prelude’s medicinal chemistry and drug development capabilities.

For comprehensive details about these developments, interested parties can visit Prelude’s website, where all related webcast recordings will be stored for a duration of 90 days.

The primary goal of Prelude Therapeutics is to bring forward innovative treatments for cancer by focusing on clinically validated pathways and addressing the needs of underserved patient populations through their highly differentiated small molecule compounds and strategic collaborations.

This announcement underscores Prelude Therapeutics' commitment to advancing precision oncology and enhancing the company's visibility and engagement within the healthcare community through these significant conferences.